Patient selection in heart failure with preserved ejection fraction clinical trials

Journal of the American College of Cardiology

Volumn 65, Issue 16, 2015, Pages 1668-1682

  Kelly, Jacob P ^a   Mentz, Robert J ^a   Mebazaa, Alexandre ^b   Voors, Adriaan A ^c   Butler, Javed ^d   Roessig, Lothar ^e   Fiuzat, Mona ^a   Zannad, Faiez ^f   Pitt, Bertram ^g   O'Connor, Christopher M ^a   Lam, Carolyn S P ^h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d STONY BROOK UNIVERSITY   (United States)

^e BAYER PHARMA AG   (Germany)

^f UNIVERSITÉ DE LORRAINE   (France)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h DEPARTMENT OF CARDIOLOGY   (Singapore)

Author keywords

clinical protocols; methodology; natriuretic peptides; patient selection

Indexed keywords

3 (1 BIPHENYL 4 YLMETHYL 3 ETHOXYCARBONYL 1 BUTYLCARBAMOYL)PROPIONIC ACID PLUS VALSARTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PERINDOPRIL; SERELAXIN; SILDENAFIL; NATRIURETIC FACTOR;

ACUTE HEART FAILURE; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CARDIOVASCULAR MORTALITY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COMORBIDITY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DYSPNEA; ECHOCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART HEMODYNAMICS; HEMODYNAMIC PARAMETERS; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; MEDICAL HISTORY; NEW YORK HEART ASSOCIATION CLASS; PATIENT COUNSELING; PATIENT SELECTION; PHENOTYPE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY ARTERY SYSTOLIC PRESSURE; REFERENCE VALUE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SENSITIVITY AND SPECIFICITY; STUDY DESIGN; SYMPTOM; ATRIAL FIBRILLATION; BLOOD; COMPLICATION; HEART FAILURE; HEART STROKE VOLUME; HEMODYNAMICS; PHYSIOLOGY;

ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HEMODYNAMICS; HUMANS; NATRIURETIC PEPTIDES; PATIENT SELECTION; STROKE VOLUME;

EID: 84928041834     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.03.043     Document Type: Review

References (96)

1. A.S. Go, D. Mozaffarian, V.L. Roger for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Executive summary: heart disease and stroke statistics - 2014 update: a report from the American Heart Association Circulation 129 2014 399 410
2. S. Tate, A. Griem, and B. Durbin-Johnson et al. Marked elevation of B-type natriuretic peptide in patients with heart failure and preserved ejection fraction J Biomed Res 28 2014 255 261
3. J.J. McMurray, M.C. Petrie, and D.R. Murdoch et al. Clinical epidemiology of heart failure: public and private health burden Eur Heart J 19 Suppl P 1998 P9 P16
4. T.E. Owan, D.O. Hodge, and R.M. Herges et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction N Engl J Med 355 2006 251 259
5. B.A. Steinberg, X. Zhao, and P.A. Heidenreich et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes Circulation 126 2012 65 75
6. C.W. Yancy, M. Jessup, and B. Bozkurt et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 e147 e239
7. J. Lindenfeld, N.M. Albert, and J.P. Boehmer et al. HFSA 2010 comprehensive heart failure practice guideline J Cardiac Fail 16 2010 e1 e194
8. Authors/Task Force Members K. Dickstein, and A. Cohen-Solal et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2008 2388 2442
9. J.J.V. McMurray, S. Adamopoulos, and S.D. Anker et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology Eur Heart J 33 2012 1787 1847
10. S. Ather, W. Chan, and B. Bozkurt et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction J Am Coll Cardiol 59 2012 998 1005
11. R.J. Mentz, J.P. Kelly, and T.G. von Lueder et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction J Am Coll Cardiol 64 2014 2281 2293
12. W.J. Paulus, and C. Tschope A novel paradigm for heart failure with preserved ejection fraction. comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation J Am Coll Cardiol 62 2013 263 271
13. S. Yusuf, M.A. Pfeffer, K. Swedberg for the CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
14. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1987 1429 1435
15. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions N Engl J Med 327 1992 685 691
16. W.J. Paulus, and J.J. van Ballegoij Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 55 2010 526 537
17. J.G. Cleland, M. Tendera, and J. Adamus et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur Heart J 27 2006 2338 2345
18. B.M. Massie, P.E. Carson, J.J. McMurray for the I-PRESERVE Investigators Irbesartan in patients with heart failure and preserved ejection fraction N Engl J Med 359 2008 2456 2467
19. B. Pitt, M.A. Pfeffer, S.F. Assmann for the TOPCAT Investigators Spironolactone for heart failure with preserved ejection fraction N Engl J Med 370 2014 1383 1392
20. S.D. Solomon, M. Zile, B. Pieske for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial Lancet 380 2012 1387 1395
21. C.S. Lam, and S.D. Solomon The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%) Eur J Heart Fail 16 2014 1049 1055
22. G.C. Fonarow, W.G. Stough, W.T. Abraham for the OPTIMIZE-HF Investigators and Hospitals Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry J Am Coll Cardiol 50 2007 768 777
23. J.S. Gottdiener, R.L. McClelland, and R. Marshall et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study Ann Intern Med 137 2002 631 639
24. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis Eur Heart J 33 2012 1750 1757
25. S.D. Solomon, N. Anavekar, H. Skali for the Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients Circulation 112 2005 3738 3744
26. N.A. Bello, B. Claggett, and A.S. Desai et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction Circ Heart Fail 7 2014 590 595
27. D.J. van Veldhuisen, A. Cohen-Solal, M. Bohm for the SENIORS Investigators Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure) J Am Coll Cardiol 53 2009 2150 2158
28. S.D. Solomon, J. Dobson, S. Pocock for the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure Circulation 116 2007 1482 1487
29. R.S. Bhatia, J.V. Tu, and D.S. Lee et al. Outcome of heart failure with preserved ejection fraction in a population-based study N Engl J Med 355 2006 260 269
30. J.J. McMurray, and C. O'Connor Lessons from the TOPCAT trial N Engl J Med 370 2014 1453 1454
31. M.A. Pfeffer, B. Claggett, and S.F. Assmann et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial Circulation 131 2015 34 42
32. R.J. Mentz, J.C. Kaski, and G.A. Dan et al. Implications of geographical variation on clinical outcomes of cardiovascular trials Am Heart J 164 2012 303 312
33. C.M. O'Connor, M. Fiuzat, and K. Swedberg et al. Influence of global region on outcomes in heart failure beta-blocker trials J Am Coll Cardiol 58 2011 915 922
34. S.L. Kristensen, L. Kober, and P.S. Jhund et al. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction Circulation 131 2015 43 53
35. A.P. Davie, C.M. Francis, and L. Caruana et al. Assessing diagnosis in heart failure: which features are any use? QJM 90 1997 335 339
36. N.D. Gillespie, G. McNeill, and T. Pringle et al. Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea BMJ 314 1997 936 940
37. B.K. Madsen, J.F. Hansen, and K.H. Stokholm et al. Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms Eur Heart J 15 1994 303 310
38. A. Ahmed, W.S. Aronow, and J.L. Fleg Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function Am Heart J 151 2006 444 450
39. S.D. Russell, M.A. Saval, J.L. Robbins for the HF-ACTION Investigators New York Heart Association functional class predicts exercise parameters in the current era Am Heart J 158 2009 S24 S30
40. R.J. Mentz, X. Mi, and P.P. Sharma et al. Relation of dyspnea severity on admission for acute heart failure with outcomes and costs Am J Cardiol 115 2015 75 81
41. S.P. Collins, P.S. Pang, and C.J. Lindsell et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes Eur J Heart Fail 12 2010 1253 1260
42. A. Mebazaa, P.S. Pang, and M. Tavares et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study Eur Heart J 31 2010 832 841
43. P.S. Pang, S.P. Collins, and K. Sauser et al. for the Assessment of dyspnea early in acute heart failure: patient characteristics and response differences between likert and visual analog scales Acad Emerg Med 21 2014 659 666
44. J.R. Teerlink, G. Cotter, B.A. Davison for the RELAXin in Acute Heart Failure (RELAX-AHF) Investigators Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial Lancet 381 2013 29 39
45. B. Steinhart, K.E. Thorpe, and A.M. Bayoumi et al. Improving the diagnosis of acute heart failure using a validated prediction model J Am Coll Cardiol 54 2009 1515 1521
46. R.S. McKelvie, M. Komajda, J. McMurray for the I-Preserve Investigators Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial J Card Fail 16 2010 128 134
47. M. Komajda, P.E. Carson, and S. Hetzel et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE) Circ Heart Fail 4 2011 27 35
48. D.J. van Veldhuisen, G.C. Linssen, and T. Jaarsma et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction J Am Coll Cardiol 61 2013 1498 1506
49. I.S. Anand, T.S. Rector, and J.G. Cleland et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial Circ Heart Fail 4 2011 569 577
50. M.M. Redfield, H.H. Chen, B.A. Borlaug RELAX Trial Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial JAMA 309 2013 1268 1277
51. F. Edelmann, R. Wachter, A.G. Schmidt Aldo-DHF Investigators Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial JAMA 309 2013 781 791
52. I.J. Neeland, B.R. Winders, and C.R. Ayers et al. Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile J Am Coll Cardiol 62 2013 752 760
53. T.J. Wang, M.G. Larson, and D. Levy et al. Impact of obesity on plasma natriuretic peptide levels Circulation 109 2004 594 600
54. S. Stavrakis, A. Pakala, and J. Thomas et al. Obesity, brain natriuretic peptide levels and mortality in patients hospitalized with heart failure and preserved left ventricular systolic function Am J Med Sci 345 2013 211 217
55. Y. Liu, Y. Xiao, and X. Chen et al. Association between plasma brain natriuretic peptide/N-terminal pro-brain natriuretic peptide levels and atrial fibrillation: evidence from a meta-analysis Chin Med J (Engl) 127 2014 2824 2828
56. L.H. Zheng, L.M. Wu, and Y. Yao et al. Impact of body mass index on plasma N-terminal ProB-type natriuretic peptides in Chinese atrial fibrillation patients without heart failure PloS One 9 2014 e105249
57. I. Agoston, C.S. Cameron, and D. Yao et al. Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction Am J Cardiol 94 2004 1003 1007
58. H. Takase, and Y. Dohi Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship Eur J Clin Invest 44 2014 303 308
59. J.J. McMurray, M. Packer, and A.S. Desai et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 2014 993 1004
60. R. Zakeri, A.M. Chamberlain, and V.L. Roger et al. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study Circulation 128 2013 1085 1093
61. B.M. Massie, C.M. O'Connor, M. Metra for the PROTECT Investigators and Committees Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure N Engl J Med 363 2010 1419 1428
62. C.S. Lam, V.L. Roger, and R.J. Rodeheffer et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study J Am Coll Cardiol 53 2009 1119 1126
63. M.J. Andersen, and B.A. Borlaug Invasive hemodynamic characterization of heart failure with preserved ejection fraction Heart Fail Clin 10 2014 435 444
64. B.A. Borlaug, R.A. Nishimura, and P. Sorajja et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction Circ Heart Fail 3 2010 588 595
65. W.J. Paulus, C. Tschope, and J.E. Sanderson et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology Eur Heart J 28 2007 2539 2550
66. J.G. Lainchbury, and A.M. Richards Exercise testing in the assessment of chronic congestive heart failure Heart 88 2002 538 543
67. P. Ponikowski, V. Mitrovic, and M. Ruda et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure Eur Heart J 35 2014 431 441
68. W. Kosmala, D.J. Holland, and A. Rojek et al. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial J Am Coll Cardiol 62 2013 1330 1338
69. M. Guazzi, M. Vicenzi, and R. Arena et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study Circulation 124 2011 164 174
70. J.K. Rogers, S.J. Pocock, and J.J. McMurray et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved Eur J Heart Fail 16 2014 33 40
71. J.T. Kowallick, S. Kutty, and F. Edelmann et al. Quantification of left atrial strain and strain rate using Cardiovascular Magnetic Resonance myocardial feature tracking: a feasibility study J Cardiovasc Magn Reson 2014 Aug 12 [E-pub ahead of print]
72. E. Kraigher-Krainer, A.M. Shah, D.K. Gupta PARAMOUNT Investigators Impaired systolic function by strain imaging in heart failure with preserved ejection fraction J Am Coll Cardiol 63 2014 447 456
73. X.X. Luo, F. Fang, and A.P. Lee et al. What can three-dimensional speckle-tracking echocardiography contribute to evaluate global left ventricular systolic performance in patients with heart failure? Int J Cardiol 172 2014 132 137
74. M.R. Stampehl, D.L. Mann, and J.S. Nguyen et al. Speckle strain echocardiography predicts outcome in patients with heart failure with both depressed and preserved left ventricular ejection fraction Echocardiography 32 2015 71 78
75. J. Wang, F. Fang, and G. Wai-Kwok Yip et al. Left ventricular long-axis performance during exercise is an important prognosticator in patients with heart failure and preserved ejection fraction Int J Cardiol 178 2014 131 135
76. Y. Izumiya, S. Hanatani, and Y. Kimura et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction Can J Cardiol 30 2014 338 344
77. F.J. Carrasco-Sanchez, L. Galisteo-Almeda, and I. Paez-Rubio et al. Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction J Card Fail 17 2011 31 38
78. L. Gullestad, T. Ueland, and J. Kjekshus et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) Eur Heart J 33 2012 2290 2296
79. R.A. de Boer, F. Edelmann, and A. Cohen-Solal et al. Galectin-3 in heart failure with preserved ejection fraction Eur J Heart Fail 15 2013 1095 1101
80. S.J. Hwang, V. Melenovsky, and B.A. Borlaug Implications of coronary artery disease in heart failure with preserved ejection fraction J Am Coll Cardiol 63 2014 2817 2827
81. B.R. Lindman, V.G. Davila-Roman, and D.L. Mann et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study J Am Coll Cardiol 64 2014 541 549
82. M.S. Maurer, and D. Mancini HFpEF: is splitting into distinct phenotypes by comorbidities the pathway forward? J Am Coll Cardiol 64 2014 550 552
83. B. Greenberg Heart failure preserved ejection fraction with coronary artery disease: time for a new classification? J Am Coll Cardiol 63 2014 2828 2830
84. S.J. Shah, D.H. Katz, and S. Selvaraj et al. Phenomapping for novel classification of heart failure with preserved ejection fraction Circulation 131 2015 269 279
85. T. Ahmad, M.J. Pencina, and P.J. Schulte et al. Clinical implications of chronic heart failure phenotypes defined by cluster analysis J Am Coll Cardiol 64 2014 1765 1774
86. S.J. Shah, D.H. Katz, and R.C. Deo Phenotypic spectrum of heart failure with preserved ejection fraction Heart Fail Clin 10 2014 407 418
87. A. Ahmed, M.W. Rich, and J.L. Fleg et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary Digitalis Investigation Group trial Circulation 114 2006 397 403
88. V.M. Conraads, M. Metra, and O. Kamp et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study Eur J Heart Fail 14 2012 219 225
89. K. Yamamoto, H. Origasa, M. Hori for the J-DHF Investigators Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF) Eur J Heart Fail 15 2013 110 118
90. F. Edelmann, G. Gelbrich, and H.D. Dungen et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study J Am Coll Cardiol 58 2011 1780 1791
91. G. Filippatos, J.R. Teerlink, and D. Farmakis et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial Eur Heart J 35 2014 1041 1050
92. A. Deswal, P. Richardson, and B. Bozkurt et al. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF) J Card Fail 17 2011 634 642
93. ClinicalTrials.gov. Efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients with preserved ejection fraction (PARAGON-HF). 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT01920711. Accessed March 11, 2015.
94. ClinicalTrials.gov. Phase IIb safety and efficacy study of four dose regimens of BAY1021189 in patients with heart failure and preserved ejection fraction suffering from worsening chronic heart failure (SOCRATES-PRESERVED). 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT01951638. Accessed March 11, 2015.
95. Institut de Recherches Internationales Servier. Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with chronic heart failure with preserved left ventricular ejection fraction (EDIFY). 2013. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002742-20/HU. Accessed March 11, 2015.
96. C.W. Yancy, M. Lopatin, L.W. Stevenson for the ADHERE Scientific Advisory Committee and Investigators Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database J Am Coll Cardiol 47 2006 76 84